Nurix Therapeutics, Inc..
NRIX.US | Research and experimental development on natural sciences and engineering
Nurix Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels. The company's primary focus is on developing drugs that target E3 ligases, a class of enzymes that regulate p...Show More
Better Health for All
20
Nurix Therapeutics' core business is entirely devoted to developing therapies for severe diseases like cancer and inflammatory disorders, with its drug candidates aimed at treating these conditions. Clinical trials for bexobrutideg (NX-5948) show objective response rates of 80.9% in CLL patients and 84.2% in WM patients, with complete and deepening responses observed, indicating exceptional health benefits.
1
The company has no revenue from products with negative health impacts. However, the safety record for bexobrutideg indicates that common treatment-emergent adverse events (AEs) include purpura/contusion (45.8%), neutropenia (29.2%), and thrombocytopenia (22.9%), with two AEs leading to drug discontinuation.
2
The company's R&D expenses were $221.6 million in Fiscal Year 2024 and $78.1 million in Q2 2025.
3
When compared to total revenues of $54.5 million (FY2024) and $44.1 million (Q2 2025), these R&D investments represent 406.6% and 177.1% of revenue respectively, demonstrating a significant investment in health innovation.
4
The company is actively conducting clinical trials, with FDA and EMA designations for its drug candidates, but there is no specific information regarding the ethical conduct of these trials beyond the reporting of adverse events.
Fair Money & Economic Opportunity
0
Nurix Therapeutics, Inc. is a biopharmaceutical company focused on drug discovery and development.
1
The provided articles do not contain any evidence that the company offers lending, deposit, or other consumer financial services.
2
Therefore, none of the KPIs related to fair money and economic opportunity, which are designed for financial institutions and consumer financial products, can be scored based on the provided rubric and evidence.
Fair Pay & Worker Respect
0
Employee feedback from 39 reviews indicates an average rating of 4.1 out of 5 stars, with 84% of employees recommending working at the company.
1
The company experienced layoffs in 2023, which was cited as a negative point regarding communication.
2
No specific regulatory actions, violations, fines, or compliance issues related to labor laws or human rights have been mentioned in the provided articles.
Fair Trade & Ethical Sourcing
0
No evidence available to assess Nurix Therapeutics, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No specific, concrete evidence was found in the provided article to assess Nurix Therapeutics, Inc. against any of the 'Honest & Fair Business' KPIs. The article offers a general overview of corporate governance but lacks quantitative data or specific details for regulatory fines, transparency benchmarks, whistleblower policies, financial restatements, audit coverage, ESG controversies, complaint resolution times, board independence, anti-corruption policies, or third-party verification.
1
Kind to Animals
0
No specific, concrete data points or facts regarding Nurix Therapeutics, Inc.'s performance on any of the 'Kind to Animals' KPIs were found in the provided articles. The articles either did not mention NRIX.US, contained no relevant information, or discussed general industry trends or other companies.
No War, No Weapons
0
The provided articles describe Nurix Therapeutics, Inc. as a biopharmaceutical company focused on the discovery and development of therapies for cancer and autoimmune diseases.
1
No specific, concrete evidence or quantitative data points were found in any of the articles regarding the company's involvement in arms manufacturing, military contracts, dual-use technologies, sales to embargoed regimes, peacebuilding initiatives, or any other activities related to the 'No War, No Weapons' ethical value. Therefore, all KPIs for this value are omitted due to a lack of explicit evidence.
Planet-Friendly Business
0
No specific quantitative data related to Planet-Friendly Business metrics is available across the provided articles. Information on emissions, renewable energy, water use, waste diversion, and other environmental performance indicators is consistently noted as missing or not provided.
1
While some articles mention a general ESG risk score or an SDG Transparency Score, these are not specific, quantitative metrics that map to any of the defined KPIs in the rubric.
Respect for Cultures & Communities
0
No evidence available to assess Nurix Therapeutics, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
No evidence available to assess Nurix Therapeutics, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No evidence available to assess Nurix Therapeutics, Inc. on Zero Waste & Sustainable Products.